Compare ADMA Biologics Inc (ADMA) vs Godaddy Inc (GDDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Godaddy Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Godaddy Inc trades at $87.01 (market cap $11.83B). The key difference: Godaddy Inc is far larger — about 5.6× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | GDDY | |
|---|---|---|
Market Cap | $2.13B | $11.83B |
Sector | Health | Technology |
52-Week High | $20.38 | $177.04 |
52-Week Low | $7.60 | $75.07 |
Enterprise Value | $2.20B | $14.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
GoDaddy (GDDY) trades at $89.32, up 0.92% on the day, with a bullish technical outlook supported by moving averages despite overbought RSI signals. The company exhibits strong profitability with a 17.32% net income margin and consistent earnings beats, though revenue growth is moderating. Recent news highlights a securities class action investigation and optimism around AI resilience, with Q2 2026 results due July 30, 2026.
The stock presents a mixed outlook: analyst consensus is bullish with a $123 price target, but legal risks and high ROE from low equity base warrant caution. Upside hinges on execution amid competitive pressures, while any negative legal developments could pressure shares near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →
